Exchange: NASDAQ·Updated 03:58 PM EDT
News
all
press releases
VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t
Viking expects oral VK2735 Phase 3 studies to begin in Q4 and believes the pill could become the first oral dual GLP-1 agonist to reach the market.
Stocktwits
More News
Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026
Biopharma M&A has surged to $106 billion across 201 deals through early June 2026, putting the sector on track for its strongest full-year total since the 2019 pre-pandemic peak, CNBC reported.
Stocktwits
LLY, NVO Stocks Led May’s GLP-1 Rally — But This Smaller ‘Differentiated Player’ Got A Bold 160% Upside Call
Truist called Viking a “differentiated player” in the crowded obesity market, highlighting its flagship VK2735 candidate and dual oral-plus-injectable GLP-1 strategy.
Stocktwits
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (Terns) (Nasdaq: TERN). The Terns acquisition reflects Mercks continued focus on sciencedriven, valueenhancing business development...
Business Wire
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Recommendation of "Hold" from Analysts
Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has earned a consensus recommendation of "Hold" from the fifteen analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, ten have assigned a hold recommen...
MarketBeat
MRK Q1 Earnings & Sales Beat Estimates, 2026 Sales View Tightened
Merck tops Q1 estimates as Keytruda drives growth and lifts 2026 EPS outlook despite acquisition charge. Sales view tightened.
Zacks
Pictet Asset Management Holding SA Boosts Stake in Terns Pharmaceuticals, Inc. $TERN
Pictet Asset Management Holding SA lifted its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 42.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,577...
MarketBeat
Terns Pharmaceuticals (NASDAQ:TERN) Earns Market Perform Rating from Oppenheimer
Oppenheimer restated a "market perform" rating and set a $58.00 target price on shares of Terns Pharmaceuticals in a research report on Monday...
MarketBeat
Buy, Sell or Hold MRK Stock With Q1 Earnings Around the Corner?
Merck heads into Q1 with strong Keytruda demand but rising pressure from generics, vaccines slump, and deal costs persist. Can it retain growth momentum?
Zacks
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in...
Business Wire